knowledge
Previous article:
Medicare details structure of new drug price negotiation program
Next article: Health insurers' Q3 question: how much care are people getting?
Next article: Health insurers' Q3 question: how much care are people getting?
focus
focus
-
Setback for rare diseases as Taysha Gene Therapies pulls back
2025-09-02 11:13 -
Biogen shutters digital health group, ends Apple study, in cost cutting move
2025-09-02 11:02 -
After a drawn out lobbying fight, ARPA
2025-09-02 09:58 -
FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial
2025-09-02 09:54 -
Medicare drug price negotiation program allowed for now
2025-09-02 09:31 -
Setback for rare diseases as Taysha Gene Therapies pulls back
2025-09-02 09:27